
    
      A prospective randomized trial was conducted to compare in AL amyloidosis ASCT (melphalan 140
      or 200 mg/m2 depending on age and clinical status supported with ASCT collected with G-CSF
      alone) and the oral regimen M-Dex (melphalan 10 mg/m2 and dexamethasone 40 mg for 4 days each
      months up to 18 months). The objectives were to compare survival and hematologic and clinical
      responses.
    
  